Study Details
Testing Inhaled Pirfenidone in People with Progressive Pulmonary Fibrosis
(IRB#: IRB_00184324)
Progressive Pulmonary Fibrosis (PPF) is a lung disease where lung tissue scars and thickens over time. This study will test a new drug called AP01, an inhaled version of a medicine called Pirfenidone, in people with PPF. The study wants to see if AP01 (inhaled pirfenidone) will help people with PPF and is safe. People in this study will be randomly chosen to be treated with AP01 or placebo. The placebo looks like AP01 but does have the medicine. AP01 and placebo are given by breathing into the lungs using a machine called a nebulizer (inhaling device). The nebulizer changes the medicine into a mist to breathe into the lungs. Being in this study requires about 13 clinic visits. Participation lasts about 60 weeks. Medical visits will be done during the study to track the health of participants.
- All genders
- Over 18 years old
- Volunteers with special conditions
- In Person
- Paid
Who can participate?
Gender: All genders
Age: Over 18 years old
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria
- Ages 18 years and older
- Diagnosis of Progressive Pulmonary Fibrosis
- Fibrosising lung disease as shown on a recently taken HRCT scan
- Able to attend in person visits at the study clinic
Exclusion Criteria
- Current treatment with oral pirfenidone
- Renal (kidney) disease
- Diagnosis of Idiopathic Pulmonary Fibrosis
- More emphysema than scarring from lung disease seen on the most recent CT scan
- A history of serious breathing problems that required a hospital stay in the 12 weeks before or during participation
Will I be paid for my time?
Yes
For more information contact:
Stefanos Athanasiadis-Lakonios
801-581-5811
IRB#: IRB_00184324
PI: Mary Beth Scholand
Department: PULMONARY
Approval Date: 2025-02-26 07:00:00
Specialties: Pulmonary
I am Interested